Zealand Pharma

451,4

DKK

-4,85 %

Mindre end 1K følgere

ZEAL

NASDAQ Copenhagen

Biotechnology & Pharmaceuticals

Health Care

Overview

Ownership

Investor consensus

Zealand Pharma er aktiv inden for bioteknologi. Særligt fokus findes på udviklingen af lægemidler til behandling af diabetes og forskellige tarmsygdomme. Virksomheden har en varieret produktportefølje med separate mærker, der sælges på globalt plan. Den største forretning er på det nordiske marked. Zealand Pharma blev grundlagt i 1997 og har hovedkontor i Søborg.

Markedsværdi

32,2 mia. DKK

Aktieomsætning

240,51 mio. DKK

Omsætning

62,69 mio.

EBIT %

-2.029,37 %

P/E

-

Udbytteafkast, %

-

Finanskalender

14.8

2025

Delårsrapport Q2'25

13.11

2025

Delårsrapport Q3'25

Alle

Analyse

Selskabsmeddelelser

ViserAlle indholdstyper

Selskabsmeddelelse6.6.2025, 20.00

Zealand Pharma increases its share capital as a result of the exercise of employee warrants

Pressemeddelelse2.6.2025, 05.00

Zealand Pharma submits Marketing Authorization Application to the European Medicines Agency for glepaglutide in short bowel syndrome

Selskabsmeddelelse27.5.2025, 20.00

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Pressemeddelelse19.5.2025, 13.00

Zealand Pharma continues to strengthen strategic leadership of innovation in obesity and related conditions with appointment of Steven Johnson as Chief Development Officer

Pressemeddelelse12.5.2025, 05.00

Zealand Pharma to participate in upcoming healthcare investor conferences in May and June 2025

Selskabsmeddelelse9.5.2025, 04.24

Zealand Pharma announces closing of collaboration and license agreement with Roche

Selskabsmeddelelse8.5.2025, 05.00

Zealand Pharma Announces Financial Results for the First Three Months of 2025

Pressemeddelelse1.5.2025, 15.05

Zealand Pharma conference call on May 8 at 2pm CET (8am ET) to present first quarter 2025 financial results

Pressemeddelelse24.4.2025, 05.00

Zealand Pharma announces first participant enrolled in Phase 2b ZUPREME-2 trial of petrelintide in people with overweight or obesity and type 2 diabetes

Pressemeddelelse23.4.2025, 13.00

Zealand Pharma appoints Utpal Singh as Chief Scientific Officer to drive next-generation peptide therapeutics discovery

Selskabsmeddelelse19.4.2025, 20.05

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

Selskabsmeddelelse19.4.2025, 20.00

Zealand Pharma launches long-term incentive programs for Zealand Pharma’s Board of Directors, Corporate Management and employees for 2025

Selskabsmeddelelse31.3.2025, 21.00

Total number of shares and voting rights in Zealand Pharma as of March 31, 2025

Selskabsmeddelelse27.3.2025, 17.20

Resolutions from Zealand Pharma's Annual General Meeting 2025

Selskabsmeddelelse25.3.2025, 16.00

Zealand Pharma major shareholder announcement: Van Herk Investments B.V.

Selskabsmeddelelse20.3.2025, 16.00

Zealand Pharma increases its share capital as a result of the exercise of employee warrants

Pressemeddelelse17.3.2025, 07.00

Zealand Pharma announces completion of enrollment in the Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity

Selskabsmeddelelse12.3.2025, 06.00

Zealand Pharma and Roche enter collaboration and license agreement to co-develop and co-commercialize petrelintide as a future foundational therapy for people with overweight and obesity

Selskabsmeddelelse20.2.2025, 12.00

Zealand Pharma convenes its Annual General Meeting 2025

Selskabsmeddelelse20.2.2025, 09.08

Correction: Zealand Pharma Announces Financial Results for the Full Year 2024

Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.